SAN DIEGO, Oct. 16, 2017 /PRNewswire/ Prometheus Laboratories Inc. introduces a comprehensive new serum test that measures
and monitors mucosal healing status in Crohn's disease patients. The new test—PROMETHEUS
® Monitr™ Crohn's Disease—is the
first of its kind, providing a valuable, noninvasive tool for patient management.
Crohn's disease has traditionally been difficult to monitor because the only available diagnostic tools have been colonoscopy and
endoscopy, both of which are invasive, expensive, and challenging for the patient. Additionally, symptoms do not necessarily correlate to
the amount of inflammation present. Monitr™ gives the physician a high degree of flexibility for assessing mucosal disease; the test can
be used as an adjunct to endoscopy or by itself, between endoscopies, allowing for more frequent, noninvasive monitoring.
"Our goal is to see patients achieve mucosal healing, or significant improvements in mucosal health," said Marla Dubinsky, M.D., Chief
of Pediatric Gastroenterology and Hepatology and Codirector of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical
Center at the Icahn School of Medicine, Mount Sinai. "To do that, we really need an objective way to view snapshots of the mucosa
without frequent scoping. The more noninvasive biomarkers we can assay to objectively evaluate the mucosa, the better off patients will
The clinical validation of the Monitr test demonstrated high accuracy and concordance rates with endoscopically visualized mucosal
disease activity in adult Crohn's disease patients, regardless of the anatomical disease location or selected treatment regimens. Monitr
will allow healthcare providers to more easily evaluate Crohn's disease patients who have suspected active disease in difficulttoreach
locations, such as the small bowel. The test can be performed with or without endoscopy, making it convenient for both the healthcare
provider and the patient. Every Monitr test report provides a single objective Mucosal Healing Index Score that can be used to assess
and track disease activity over time.
"Monitr is a powerful patient counseling tool that addresses an unmet need. It can help healthcare providers discuss difficult treatment
decisions with their patients," said Warren Cresswell, General Manager and Head of Diagnostics at Prometheus Laboratories Inc.
"Monitr represents our continued focus and commitment to helping improve patient care through innovation and testing excellence."
Prometheus is presenting Monitr clinical validation and test performance data during the 2017 American College of Gastroenterology
(ACG) conference, October 1318, in Orlando, FL.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical
and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the
principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is expanding product development to
oncology testing. The company complements its proprietary diagnostic testing services with therapeutic products. By integrating
therapeutics and diagnostics, Prometheus provides physicians with more targeted solutions to optimize care for their patients.
Prometheus became part of Nestlé Health Science in 2011. For more information about Prometheus, please visit
About Nestlé Health Science
Nestlé Health Science, a whollyowned subsidiary of Nestlé, is a healthscience company engaged in advancing the role of nutritional
therapy to change the course of health for consumers, patients, and its partners in healthcare. Nestlé Health Science's portfolio of
nutrition solutions, diagnostics, devices, and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and
acute care, obesity care, healthy aging, and gastrointestinal and brain health. Through investing in innovation and leveraging leadingedge
science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value, and quality of
life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne),
Switzerland. For more information, please visit: www.nestlehealthscience.com.
PROMETHEUS, the Link Design, For the person in every patient, and Monitr are trademarks or registered trademarks of Société des
Produits Nestlé S.A. Vevey, Switzerland.
Contact for the media:
Geri VenaShores, Head of Marketing